BioCardia (NASDAQ:BCDA – Get Free Report) and Moderna (NASDAQ:MRNA – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.
Earnings and Valuation
This table compares BioCardia and Moderna”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $71,000.00 | 173.35 | -$11.57 million | ($4.19) | -0.64 |
| Moderna | $3.20 billion | 4.47 | -$3.56 billion | ($9.28) | -3.99 |
BioCardia has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | -1,999.77% | N/A | -208.38% |
| Moderna | -110.04% | -28.74% | -21.83% |
Risk & Volatility
BioCardia has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for BioCardia and Moderna, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 0 | 0 | 1 | 1 | 3.50 |
| Moderna | 4 | 15 | 3 | 1 | 2.04 |
BioCardia presently has a consensus target price of $25.00, indicating a potential upside of 831.10%. Moderna has a consensus target price of $60.63, indicating a potential upside of 63.56%. Given BioCardia’s stronger consensus rating and higher probable upside, research analysts plainly believe BioCardia is more favorable than Moderna.
Institutional and Insider Ownership
20.6% of BioCardia shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Comparatively, 15.7% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
BioCardia beats Moderna on 8 of the 14 factors compared between the two stocks.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
About Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
